Overview / Abstract: |
The clinical benefits of early, aggressive treatment in MS have been demonstrated via slower progression of disease and improved patient quality of life. Disease-free status, or “no evidence of disease activity” (NEDA), is now a realistic treatment goal. However, with 15 current FDA-approved disease-modifying therapies (DMTs) available, it is challenging to personalize selection of the optimal agent for each patient. Achieving New Treatment Goals in Multiple Sclerosis: Strategies for Initial Treatment Selection and Patient Engagement will provide clinicians with current evidence on biomarker development, comparative treatment effectiveness, monitoring, and maintenance regimens. Participants will explore safety and efficacy data for current and emerging DMTs and NEDA treatment goals. Because of the long-term nature of MS management, effective patient engagement is crucial to achieve the best possible outcomes. The activity will also provide physicians with strategies to foster patient engagement within the time constraints of the typical patient visit. EDUCATIONAL OBJECTIVES - At the conclusion of this activity, participants should be able to demonstrate the ability to: - Recognize the benefits of starting an optimal DMT early enough to achieve the new treatment goal of “no evidence of disease activity” (NEDA) |
Expiration |
Jul 12, 2019 |
Discipline(s) |
Physician CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
Jointly provided by PCME, CMSC, and Rockpointe. In collaboration with Health Union |
Accreditation |
AACME - 1.00 AMA PRA Category 1 Credit™; CMSC - 1.0 credit of continuing nursing education |
Presenters / Authors / Faculty |
Alina Ahsan Laura Kolaczkowski |
Sponsors / Supporters / Grant Providers |
This program was supported by an educational grant from Sanofi Genzyme. |
Keywords / Search Terms |
Rockpointe Multiple Sclerosis, MS, Neurology, CME, Free CME, Continuing Medical Education, CME Webcourse, Primary Care, Primary Care Provider, On-Demand CME Free CE CME |